Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinomaOctober 18, 2007Portal venous tumor thrombus (PVTT) is a crucial factor that can worsen the prognosis of patients with hepatocellular carcinoma (HCC). It often leads to extensive spreading of the tumor throughout the liver, and can increase portal venous blood pressure, resulting in the fatal rupture of esophageal varices, and can decrease portal flow which causes ascites, jaundice, hepatic encephalopathy, and liver failure. However, there is no effective useful therapy for HCC combined with PVTT. Therefore, there is an urgent need for new and active drugs and combination chemotherapy of advanced HCC. A total of 10 consecutive patients with Stage IVA HCC accompanied by PVTT were studied prospectively to examine the efficacy of treatment by intra-arterial infusion of a chemotherapeutic agents consisting of etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil by Ishikawa, et al. The median survival time after the therapy was 457.2 days; the 1-year survival rate was 70 %. Adverse reactions were tolerable.
Although the prognosis of most patients with HCC by PVTT is poor, our combination chemotherapy may induce long-term survival and is an effective treatment and produced anti-tumor activity with tolerable adverse effects in patients for advanced HCC accompanied by PVTT. Intra-arterial combination chemotherapy is useful and inducing long-term survival for advanced HCC accompanied by PVTT. Further prospective randomized clinical trials of chemotherapy for HCC with PVTT are needed. World Journal of Gastroenterology | |||||||||||||||||||||
|
Related Chemotherapy Current Events and Chemotherapy News Articles Sensitive nanowire disease detectors made by Yale scientists Yale scientists have created nanowire sensors coupled with simple microprocessor electronics that are both sensitive and specific enough to be used for point-of-care (POC) disease detection, according to a report in Nano Letters. On the trail of a targeted therapy for blood cancers nvestigators from the Herman B Wells Center for Pediatric Research at the Indiana University School of Medicine are focusing on a family of blood proteins that they hope holds a key to decreasing the toxic effects of chemotherapy in children and adults. Hodgkin lymphoma -- new characteristics discovered Researchers are still discovering new characteristics of Hodgkin lymphoma, a common form of cancer of the lymphatic system. The malignant cells are derived from white blood cells (B cells), but have lost a considerable part of the B cell-specific gene expression pattern. Bisphenol A linked to chemotherapy resistance Exposure to bisphenol A (BPA) may reduce the effectiveness of chemotherapy treatments, say University of Cincinnati (UC) scientists. Pediatric study finds alternatives for radiation of low-grade brain tumors A multi-institutional study led by researchers at The University of Texas M. D. Anderson Cancer Center has found that using chemotherapy alone and delaying or avoiding cranial radiation altogether can be effective in treating pediatric patients with unresectable or progressive low-grade glioma. Mayo researchers explore issues related to multiple myeloma treatment Multiple myeloma (MM) is a cancer of plasma cells that affects approximately 3 in 100,000 people each year. Although there is no cure for this disease, researchers have developed treatments that help relieve pain, control complications, and slow the progress of MM in many patients. News from Cancer: Disparities in head and neck cancer patients A new analysis finds considerable disparities in survival related to race and socio-economic status among patients with head and neck cancer. Nanodiamond drug device could transform cancer treatment A Northwestern University research team has developed a promising nanomaterial-based biomedical device that could be used to deliver chemotherapy drugs locally to sites where cancerous tumors have been surgically removed. Children's National researchers develop novel anti-tumor vaccine A novel anti-tumor vaccine for neuroblastoma and melanoma developed by scientists and clinicians at Children's National Medical Center in collaboration with investigators from the University of Iowa is showing significant impact on tumor growth in mice. Surgical treatment provides new option for some colorectal cancer patients Research out of Wake Forest University School of Medicine suggests that a surgical technique not traditionally used in advanced abdominal cancer may be a viable treatment option for some patients previously thought to be untreatable, offering the real possibility of extending survival for those patients. More Chemotherapy Current Events and Chemotherapy News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||